What does PD-1/PD-L1 immunotherapy involve?

This treatment uses Chinese-manufactured checkpoint inhibitors, such as Tislelizumab or Sintilimab, which are administered intravenously over approximately 30 minutes every three weeks. These drugs block the PD-1/PD-L1 pathway, reactivating your immune system's T-cells to recognize and attack cancer cells. It is an outpatient procedure, so you can return home shortly after each infusion.